|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7690 EUR | -0.13% |
|
-2.66% | -19.90% |
| 05-22 | Transgene SA Announces Board Appointments | CI |
| 04-13 | Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bearish | Bearish |
| Resistance | 0.854 | 0.854 | 1.005 |
| Spread/Res. | -9.95% | -9.95% | -23.48% |
| Spread/Supp. | +4.77% | +4.77% | +3.92% |
| Support | 0.734 | 0.734 | 0.74 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- TNG Stock
- Charts Transgene
Select your edition
All financial news and data tailored to specific country editions
